OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Olawaiye on Next Steps for Investigating Relacorilant in Platinum-Resistant Ovarian Cancer

August 6th 2025

Alexander B. Olawaiye, MD, discusses future research directions with relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

Dr Popat on JNJ-5322 in Relapsed/Refractory Multiple Myeloma

August 5th 2025

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, discusses data with the trispecific antibody JNJ-5322 in relapsed/refractory multiple myeloma.

Dr Cascone on Perioperative Nivolumab in Resectable NSCLC

August 5th 2025

Tina Cascone, MD, PhD, discusses of perioperative nivolumab vs placebo in patients with resectable non–small cell lung cancer.

Dr Dorritie on the Role of Quadruplet Regimens in Multiple Myeloma

August 5th 2025

Kathleen A. Dorritie, MD, discusses the role of quadruplet regimens for the treatment of patients with multiple myeloma.

Dr Wong on Survival Outcomes and Molecular Characteristics of Patients with Early-Onset CRC

August 5th 2025

Evelyn Y.T. Wong, MD, discusses survival outcomes and molecular characteristics of patients with early-onset colorectal cancer from a cohort in Singapore.

Dr Kudo on Evaluating Nivolumab/Ipilimumab in Unresectable HCC

August 5th 2025

Masatoshi Kudo, MD, PhD, discusses a MAIC evaluating nivolumab/ipilimumab vs durvalumab/tremelimumab and atezolizumab/bevacizumab for unresectable HCC.

Dr Haas on Evolutions in Clinical Trial Design in the RCC Treatment Paradigm

August 4th 2025

Naomi B. Haas, MD, discusses previously conducted trials that supported the initiation of the KEYNOTE-564 trial of adjuvant pembrolizumab in RCC.

Dr George on the Clinical Relevance of Targetable Mutations in GIST

August 4th 2025

Suzanne George, MD, discusses the evolving development of targeted therapies for patients with gastrointestinal stromal tumor.

Dr McKay on the Role of Casdatifan Plus Cabozantinib in Clear Cell RCC

August 4th 2025

Rana R. McKay, MD, FASCO, details the significance of casdatifan plus cabozantinib demonstrating better responses vs the respective agents alone in ccRCC.

Dr Maese on Asparaginase-Based Regimens in Adult/Young Adult ALL

August 4th 2025

Luke Maese, DO, discusses treatment considerations for asparaginase-containing regimens in adult and young adult patients with ALL.

Dr Shah on Outcomes With Checkpoint Inhibition in Patients With Cancer and Pre-Existing Neurologic Autoimmune Disorders

August 4th 2025

Shailee S. Shah, MD, shares data on the frequency and severity of NAID exacerbation with ICIs in patients with cancer.

Dr Tan on the Ongoing Investigation of Adaptive Treatment Intensification Strategies in RCC

August 1st 2025

Alan Tan, MD, discusses current and future avenues for evaluating adaptive immunotherapy approaches in treatment-naive metastatic RCC.

Dr Tan on the Rationale for Evaluating an Adaptive Immunotherapy Strategy in Previously Untreated RCC

August 1st 2025

Alan Tan, MD, discusses the rationale for evaluating an adaptive approach to immunotherapy de-escalation in patients with RCC achieving a CR.

Dr Khan on the Role of Acalabrutinib in the Current CLL Treatment Paradigm

August 1st 2025

Cyrus M. Khan, MD, discusses how acalabrutinib fits into the current treatment paradigm in chronic lymphocytic leukemia.

Dr Pelz on the Role of Minimally Invasive Surgical Techniques in Lung Cancer

August 1st 2025

Geoffrey B. Pelz, MD, discusses the role of minimally invasive surgical approaches for the treatment of patients with lung cancer.

Dr Braun on Fundamental Immune Defects in Chromophobe RCC

July 31st 2025

David A. Braun, MD, PhD, discusses immune defects in patients with chromophobe RCC vs clear cell RCC.

Dr Sinicrope on the Clinical Implications of the ATOMIC Trial for Stage III dMMR CRC

July 31st 2025

Frank A. Sinicrope, MD, discuses the implications of data with atezolizumab plus adjuvant mFOLFOX6 for the management of stage III, dMMR colon cancer.

Dr Kuerer on the Safety, Feasibility of Omitting Surgery in Select Patients With HER2+, Triple-Negative Breast Cancer

July 31st 2025

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses the feasibility of eliminating surgery in select patients with a pCR after neoadjuvant therapy for breast cancer.

Dr Riedel on the Role of the Multidisciplinary Team in PEComa Management

July 31st 2025

Richard F. Riedel, MD, discusses the importance of multidisciplinary PEComa management and the role of sarcoma specialists in this disease setting.

Dr Sonpavde on OS Data With Ipilimumab/Nivolumab in Previously Untreated, Advanced Urothelial Carcinoma

July 31st 2025

Guru P. Sonpavde, MD, details overall survival data with ipilimumab/nivolumab vs gemcitabine/platinum in previously untreated, advanced urothelial cancer.